Verified factor-similar pair

AVUV vs DFAT

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB HML RMW
Similarity score
87
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • DFAT has the higher backtested relative Sharpe (1.348 vs 1.114).
  • AVUV has the lower published fee (0.25% vs 0.28%).
  • DFAT is cheaper on dividend valuation (105 vs 132, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

AVUV

Avantis U.S. Small Cap Value ETF
SMB HML RMW
Adj. R2
0.976
Rel. Sharpe
1.114
Mkt beta
1.06
AUM
US$24.8B
MER
0.25%
Valuation
132

DFAT

Dimensional U.S. Targeted Value ETF
SMB HML RMW
Adj. R2
0.978
Rel. Sharpe
1.348
Mkt beta
1.00
AUM
US$13.1B
MER
0.28%
Valuation
105

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
AVUV
+0.90
|t|
+16.5
DFAT
+0.87
|t|
+18.9
diff +0.03
HML
AVUV
+0.53
|t|
+11.7
DFAT
+0.41
|t|
+8.4
diff +0.13
RMW
AVUV
+0.27
|t|
+5.0
DFAT
+0.24
|t|
+5.6
diff +0.03
CMA
AVUV
-0.04
|t|
-0.7
DFAT
+0.05
|t|
+0.8
diff -0.09
UMD
AVUV
-0.01
|t|
-0.3
DFAT
-0.04
|t|
-1.3
diff +0.03

Why This Pair Matches

Exposure level
86
Exposure shape
100
Mkt beta diff
0.06
Rel. Sharpe diff
0.235

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

AVUV fund page DFAT fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.